WithdrawnPhase 4

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Stopped: Investigator left institution

United States0Started 2018-03-01

Plain-language summary

Clostridium difficle infection is the leading cause of hospital acquired infection and infectious diarrhea in hospitalized patients. Eradication treatment for this infection is the challenging tasks for clinicians due to treatment resistance developed from new hypervirulent strains. The recurrence rate of this infection is around 20% and there is high likelihood(60-70%) of another episode after index recurrence. Given constant challenge new treatment options are under study. Aim of the study is to evaluate if use of bismuth subsalicylate (BSS) can decrease the length of stay in patients admitted with Clostridium difficile infection. Secondarily investigators will also see if there is any impact of BSS in decrease the recurrence.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 or older * Hospitalized patient with documented positive stool test for CDiff * Able and willing to provide informed consent Exclusion Criteria: * Pregnancy * Breastfeeding * Known allergy to BSS or other salicylates, including aspirin * History of bleeding disorder * History of gastrointestinal bleed, * History of gastrointestinal ulcer * Chronic use of anticoagulants * Chronic NSAID use

What they're measuring

Length of stay

Timeframe: 70 days (study period = 14 days of antibiotic treatment plus 8 weeks/56 days post treament completion)

Trial details

NCT IDNCT03592082

SponsorBassett Healthcare

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-07-01

View on ClinicalTrials.gov More Clostridium Difficile Infection trials